New NASH drug J2H-1702 begins first human safety tests
NCT ID NCT06308861
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This early-stage trial tested the safety and tolerability of a new drug called J2H-1702, designed for non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. It involved 100 healthy men aged 19 to 45. The study was placebo-controlled and dose-escalating to find the safest dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
J2H Biotech
Suwon, Gyeonggi-do, 16684, South Korea
Conditions
Explore the condition pages connected to this study.